SARS-CoV vaccine development can help identify potential vaccine candidates for SARS-CoV-2. Vaccine strategies using the full spike protein, subunits of the spike protein, or specific spike protein epitopes appear most promising. The receptor-binding domain of the spike protein subunit can induce strong neutralizing antibodies and could be used in vaccines either through recombinant proteins or vectors encoding this domain. Due to genetic similarity between SARS-CoV-2 and SARS-CoV, vaccines proven effective against SARS-CoV may be repurposed for SARS-CoV-2. However, differences in the receptor-binding domain mean antibodies to SARS-CoV may provide lower cross-protection against COVID-19. Further genetic analysis is needed.
SARS-CoV vaccine development can help identify potential vaccine candidates for SARS-CoV-2. Vaccine strategies using the full spike protein, subunits of the spike protein, or specific spike protein epitopes appear most promising. The receptor-binding domain of the spike protein subunit can induce strong neutralizing antibodies and could be used in vaccines either through recombinant proteins or vectors encoding this domain. Due to genetic similarity between SARS-CoV-2 and SARS-CoV, vaccines proven effective against SARS-CoV may be repurposed for SARS-CoV-2. However, differences in the receptor-binding domain mean antibodies to SARS-CoV may provide lower cross-protection against COVID-19. Further genetic analysis is needed.
SARS-CoV vaccine development can help identify potential vaccine candidates for SARS-CoV-2. Vaccine strategies using the full spike protein, subunits of the spike protein, or specific spike protein epitopes appear most promising. The receptor-binding domain of the spike protein subunit can induce strong neutralizing antibodies and could be used in vaccines either through recombinant proteins or vectors encoding this domain. Due to genetic similarity between SARS-CoV-2 and SARS-CoV, vaccines proven effective against SARS-CoV may be repurposed for SARS-CoV-2. However, differences in the receptor-binding domain mean antibodies to SARS-CoV may provide lower cross-protection against COVID-19. Further genetic analysis is needed.
S protein-based vaccine development in SARS-CoV will help to identify potential S protein vaccine candidates in SARS-CoV-2. Therefore, vaccine strategies based on the whole S protein, S protein subunits, or specific potential epitopes of S protein appear to be the most promising vaccine candidates against coronaviruses. The RBD of the Sl subunit of S protein has a superior capacity to induce neutralizing antibodies. This property of the RBD can be utilized for designing potential SARS-CoV vaccmes either by using RBD-containing recombinant proteins or recombinant vectors that encode RBD (175). Hence, the superior genetic similarity existing between SARS-CoV-2 and SARS- CoV can be utilized to repurpose vaccines that have proven in vitro efficacy against SARS-CoV to be utilized for SARS-CoV-2. The possibility of cross- protection in COVID-19 was evaluated by comparing the S protein sequences of SARS-CoV-2 with that of SARS-CoV. The comparative analysis confirmed that the variable residues were found concentrated on the Sl subunit of S protein, an important vaccine target of the virus (150). Hence, the possibility of SARS-CoV-specific neutralizing antibodies providing cross-protection to COVID-19 might be lower. Further genetic analysis is required